晚期突变型胃型宫颈腺癌的非部位特异性PARP抑制剂维持治疗：一例报告
Site-agnostic PARP-inhibitor maintenance therapy of advanced stage mutated gastric-type endocervical adenocarcinoma: A case report.
作者信息
Tostrud Lauren Jill, Somasegar Sahana, Renz Malte
机构信息
Department of Obstetrics & Gynecology, Stanford University School of Medicine, Palo Alto, CA, United States.
Gynecologic Oncology Division, Stanford University School of Medicine, Palo Alto, CA, United States.
出版信息
Gynecol Oncol Rep. 2024 May 1;53:101406. doi: 10.1016/j.gore.2024.101406. eCollection 2024 Jun.
• Gastric-type endocervical adenocarcinomas (GEA) are rare, aggressive cancers with limited therapeutic options. • Although therapeutic effects of PARP-inhibitors in non-BRCA-associated cancers might be limited, clinical data is sparse. • Given limited treatment options and poor prognosis of GEA, somatic mutation testing, and PARP-inhibitor maintenance can be considered.
• 胃型宫颈内膜腺癌（GEA）是罕见的侵袭性癌症，治疗选择有限。
• 虽然PARP抑制剂在非BRCA相关癌症中的治疗效果可能有限，但临床数据稀少。
• 鉴于GEA的治疗选择有限且预后不良，可考虑进行体细胞突变检测和PARP抑制剂维持治疗。
Zotero 插件